Day Zero Diagnostics

Active#21 worldwide · In-vitro diagnostics

Estimated valuation · In-vitro diagnostics · United States

Develops sequencing-based tests that identify bacterial species and antibiotic resistance directly from patient samples to speed treatment of serious infections.

Healthtech›In-vitro diagnostics dayzerodiagnostics.com

HQUnited States

Last roundFinancing round (series not stated) · Oct 2023

Estimated valuation

AI · In-vitro diagnostics ranking (worldwide)

≈ USD 83MUSD 55–120M · Tens of M$

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Hectocorn

Anchor: Last known equity round: Financing round (series not stated) · USD 16M · Oct 2023

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
In-vitro diagnostics · worldwide	Top 25	#21	Edition 0 · Oct 2026	12 Apr 2027

Rank historyOct 2026 · #21 In-vitro diagnosticsFirst edition: no movements yet.

Funding history

Date	Round	Amount	Type	Investors
Oct 2023	Financing round (series not stated)	USD 16M	Equity	—

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Day Zero Diagnostics as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $83MUndervalued or overvalued?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Day Zero Diagnostics whether or not it has agreed: your intention joins the pool on Day Zero Diagnostics, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back Day Zero Diagnostics Or back healthtech in United States

Pool on Day Zero DiagnosticsBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Day Zero Diagnostics?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in in-vitro diagnostics

Full in-vitro diagnostics ranking →

Lucence#20SingaporeHundreds of M$Tethis#22ItalyTens of M$Lucis#19FranceHundreds of M$Ilara Health#23KenyaTens of M$

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.